SIMSA Act of 2025
- Sponsor
- Sen. Grassley, Chuck [R-IA]
- Committees
- Judiciary Committee (primary)
- Last action
- Nov 20, 2025
Bottom line
The SIMSA Act of 2025 aims to enhance federal control over imported synthetic drug analogues by creating a dedicated scheduling mechanism and strengthening enforcement, with provisions for legitimate research and a sentencing review process.
What it actually does
This bill amends the Controlled Substances Act to create a new 'Schedule A' specifically for controlled substance analogues that are imported or offered for import into the United States. It establishes criteria for defining these analogues, outlines procedures for their temporary and permanent scheduling by the Attorney General, and imposes significant penalties for violations involving Schedule A substances. Additionally, it sets forth false labeling prohibitions and new registration requirements for legitimate research and industrial uses of these substances.
Proponents argue
Supporters argue that this bill is a critical step to close existing loopholes in the Controlled Substances Act that allow dangerous synthetic drugs, often imported, to proliferate and contribute to the ongoing public health crisis. They contend it provides law enforcement with necessary tools to quickly identify, schedule, and penalize the trafficking of these rapidly evolving substances, thereby protecting communities and saving lives.
Opponents contend
Critics may contend that the bill's broad definitions for 'analogue' and the Attorney General's authority for temporary scheduling without immediate judicial review could lead to overreach, potentially impacting legitimate scientific research or inadvertently criminalizing substances with unclear abuse potential. Concerns might also be raised about the severity of penalties and the potential for disproportionate sentencing, despite the included review mechanism.
The bill is relatively concise, but its amendments to existing law and the technical nature of drug scheduling and chemical definitions require careful reading to fully grasp its implications.
Section 2
Establishment of Schedule A for Imported Analogues
This section amends the Controlled Substances Act to create a new 'Schedule A' for drugs or substances that are imported, or offered for import, into the United States. To qualify for Schedule A, a substance must have a chemical structure substantially similar to an existing controlled substance and an actual or predicted stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than an existing controlled substance. It also specifies that predicted effects can be based on chemical structure, structure-activity relationships, binding receptor assays, potential for abuse, and clandestine activity.
Supporters argue
Proponents argue that Schedule A is essential to address the rapid emergence of new synthetic drugs that are chemically altered to evade existing scheduling, providing a dedicated and agile mechanism to control these substances specifically at the point of import.
Critics contend
Opponents may argue that the broad definition of 'substantially similar' and 'predicted effect' could lead to the scheduling of substances without sufficient scientific evidence of their harm or abuse potential, potentially sweeping in legitimate compounds.
Tradeoffs
The provision balances the need for rapid response to new synthetic drugs with the potential for broad interpretation of chemical and pharmacological similarity, which could impact substances not yet fully understood.
Section 3
Temporary and Permanent Scheduling Procedures for Schedule A
This section grants the Attorney General the authority to issue temporary orders adding a drug or substance to Schedule A if it meets the criteria and will help prevent abuse. These temporary orders take effect 30 days after Federal Register notice and expire after 5 years, with a possible 180-day extension during permanent scheduling proceedings. Temporary orders are not subject to judicial review. Permanent scheduling can occur after 3 years, unless the Secretary of Health and Human Services (HHS) determines the substance lacks sufficient abuse potential, in which case the temporary order must be terminated.
Section 4
Enhanced Penalties for Schedule A Violations
This section amends the Controlled Substances Import and Export Act to include Schedule A substances in its penalty provisions. It establishes a term of imprisonment of not more than 20 years for violations involving Schedule A substances, with a potential life sentence if death or serious bodily injury results from the use of the substance. Repeat felony drug offenders face increased penalties, including up to 30 years imprisonment or life, and higher fines. Mandatory supervised release terms are also imposed.
Section 5
Prohibition on False Labeling of Schedule A Substances
This section makes it unlawful to import or export a Schedule A substance or product containing one, with intent to manufacture, distribute, or dispense, unless it is clearly labeled using the International Union of Pure and Applied Chemistry (IUPAC) nomenclature. It provides exemptions for products that are subject to an approved application under the Federal Food, Drug, and Cosmetic Act (e.g., FDA-approved drugs) or are intended solely for investigational use in an effective investigational new drug application.
Section 6
Registration Requirements for Schedule A Substances and Research
This section establishes new registration requirements for applicants seeking to import or export Schedule A substances. Registration is granted if the substance is for approved research, analytical, or industrial purposes and is consistent with public interest and international treaties. It outlines factors for determining public interest, such as diversion control and compliance with law. It also allows persons already conducting research on a substance when it is added to Schedule A to continue under certain conditions, including submitting a registration application within 30 days and potentially receiving an expedited hearing if denied. Existing Schedule I or II registrants do not need a separate Schedule A registration.
Section 8
Sentencing Review for Descheduled or Rescheduled Substances
This section allows individuals convicted of offenses involving a Schedule A substance to petition the court for a sentencing reduction hearing if that substance is subsequently descheduled or rescheduled to a schedule with lower penalties. The court must conduct this hearing within 30 days of the petition and may modify the sentence as if the descheduling or rescheduling had been in effect at the time the original offense was committed.
This subsection defines how a 'predicted stimulant, depressant, or hallucinogenic effect' on the central nervous system can be determined for Schedule A substances. It allows such prediction to be based on chemical structure, structure-activity relationships, binding receptor assays, current or relative potential for abuse, clandestine activity, or capacity to cause dependence.
Section 2(b)(6)(B)
Why it matters:This is standard legislative practice for defining technical criteria within a broader statutory framework, providing the operational details for the Attorney General's authority.
Case for: Supporters argue that these specific criteria provide necessary flexibility and scientific grounding for the Attorney General to make informed decisions about the potential effects of novel synthetic substances, even without extensive human trials.
Case against: Critics might argue that relying on 'predicted' effects, especially those based on structure-activity relationships or clandestine activity, grants significant discretion to the Attorney General and could lead to the scheduling of substances based on incomplete or speculative data, potentially impacting legitimate research.
Estimated impact: This provision grants broad discretion to the Attorney General in determining which substances qualify for Schedule A, significantly influencing the scope of the new schedule.
This paragraph explicitly states that a temporary scheduling order issued under the new Schedule A provisions 'shall not be subject to judicial review.'
Section 3(4)
Why it matters:This is a common legislative tactic in drug emergency scheduling to ensure rapid action without immediate legal challenges, but it can be seen as limiting due process.
Case for: Proponents argue that immediate judicial review would undermine the purpose of temporary scheduling, which is to quickly remove dangerous substances from circulation. Delays caused by litigation could allow harmful drugs to spread further.
Case against: Critics contend that the absence of judicial review for up to five years (plus extension) for a temporary scheduling order could lead to arbitrary or scientifically unfounded decisions, with no immediate legal recourse for affected parties, including legitimate researchers or businesses.
Estimated impact: This provision significantly limits the ability of affected parties to challenge temporary Schedule A designations in court, potentially for several years.